Table 2 Characteristics of included articles
Characteristics | Count | % | |
|---|---|---|---|
Intervention type (N = 86) | Behavioral/educational | 17 | 19.8% |
Dialysis technology/technique | 15 | 17.4% | |
Non-pharmaceutical other | 2 | 2.3% | |
Nutritional supplement | 12 | 14.0% | |
Pharmaceutical | 29 | 33.7% | |
Vascular access technology/technique | 11 | 12.8% | |
Number of sites (N = 86) | Multi center | 27 | 31.4% |
Single center | 59 | 68.6% | |
Sample size (N = 86) | Greater than 50 | 22 | 25.6% |
50 or less | 64 | 74.4% | |
Industry funded (N = 86) | Yes | 26 | 30.2% |
No | 60 | 69.8% | |
Location of study by continent (N = 86) | Africa | 1 | 1.2% |
Asia | 13 | 15.1% | |
Australia/New Zealand | 6 | 7.0% | |
Europe | 24 | 27.9% | |
North America | 42 | 48.8% | |
Year of publication (N = 86) | 1990–1995 | 1 | 1.2% |
1996–2000 | 8 | 9.3% | |
2001–2005 | 10 | 11.6% | |
2006–2010 | 15 | 17.4% | |
2011–2015 | 38 | 44.2% | |
2016–2018 | 14 | 16.3% | |
Journal endorses CONSORT (only published in 2010 or later)* (N = 56) | Yes | 24 | 42.9% |
No | 32 | 57.1% | |
Journal endorses CONSORT (all years, all published before 2010 set to No)** (N = 86) | Yes | 24 | 27.9% |
No | 62 | 72.1% | |
Prelude to definitive trial (N = 86) | Yes | 15 | 17.4% |
No | 71 | 82.6% | |